Long-Term Follow-Up of A Two-Stage Dose-Escalation Study to Evaluate the Safety and Efficacy of Bilateral Intraparenchymal Thalamic and Intracisternal/Intrathecal Admin of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Cobnabexagene anvuparvovec (Primary)
- Indications Sandhoff disease; Tay-Sachs disease
- Focus Adverse reactions
- 03 Oct 2024 New trial record